TALS News and Press, Talaris Therapeutics Inc. From 11/12/21

Talaris Therapeutics (NASDAQ:TALS): Q3 GAAP EPS of -$0.32 misses by $0.06. Cash, cash equivalents and marketable securities of $254.7M Press Release For further details see: Talaris Therapeutics EPS misses by $0.06

Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients BOSTON and LOUISVILLE, Ky., Nov. 12, 20...

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune disease...

Talaris Therapeutics (NASDAQ:TALS) announced the first clinical update on the Phase 3 FREEDOM-1 study, which was designed to evaluate its investigational cell therapy, FCR001 in living donor kidney transplant (LDKT) recipients. In the open label study involving 120 adult LDKT recipients ...

First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with stable kidney function All Phase 3 patients who received FCR001 at least three ...

Read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Talaris Therapeutics (NASDAQ:TALS) announces the initiation of a mid-stage trial of the company's cell therapy FCR001 in delayed tolerance induction. The Phase 2 trial will explore the safety and efficacy of the cell therapy to induce immune tolerance to a transplanted kidney in pat...

BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain sev...